W. L. Gore & Associates (Gore) today is announcing commercial availability in the US of the GORE® Hybrid Vascular Graft. The Gore device expands treatment options and improves blood flow for dialysis access patients with end-stage renal disease (ESRD). More than 130 dialysis access patients have been successfully treated with the GORE Hybrid Vascular Graft. Three month follow-up data for newly created access implants demonstrates a trend toward a reduction in revision procedures, thrombosis events and seroma, as compared to historical graft data. In the United States, more than 300,000 people suffer from ESRD and are in need of dialysis.
